Phentermine's Impact on Treatment in Teens
NCT07282340
This study is recruiting at 8 US sites in 8 states, according to its ClinicalTrials.gov record last updated .
Summary
PhITT is a Phase IIb, multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of phentermine (16 mg daily) in adolescents aged 12 to <18 years with obesity. Conducted across approximately 10 sites within the IDeA States Pediatric Clinical Trials Network (ISPCTN), the study aims to enroll up to 240 participants and then randomize up to 198 who meet eligibility criteria, randomized in a 2:1 ratio to phentermine or placebo over a 52-week treatment period, followed by a 2-week withdrawal assessment.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Childhood Obesity
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 12 to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Russell McCulloh, MD
- Last updated on ClinicalTrials.gov
- October 7, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Delaware · 1
- Nemours Children's Hospital · Wilmington, DE
Kentucky · 1
- Novak Center for Children's Health · Louisville, KY
Louisiana · 1
- Pennington Biomedical Research Center · Baton Rouge, LA
Missouri · 1
- Children's Mercy Hospital · Kansas City, MO
New Hampshire · 1
- Dartmouth Hitchcock Medical Center · Lebanon, NH
New Mexico · 1
- University of New Mexico Health Sciences Center · Albuquerque, NM
Oklahoma · 1
- The University of Oklahoma Health Sciences Children's Hospital · Oklahoma City, OK
South Carolina · 1
- Prisma Health-Midlands Children's Hospital · Columbia, SC
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.